

5th ICDS Programme

Tuesday, 19th May

SESSION I: 14:00-15:30 Chair: Riley T.			
14:00-14:15		Rupnik, M.	OPENING
14:15-15:00	INV1	Gerding, D.	KEYNOTE LECTURE - MILESTONES IN <i>C. difficile</i> RESEARCH
15:00-15:30	INV2	Bouza, E.	THE SPECTRUM OF <i>C. difficile</i> INFECTION (CDI) IN A GENERAL HOSPITAL. CASES AND SITUATIONS FROM THE REAL LIFE
15:30-16:00 COFFEE BREAK / posters to be displayed			
SESSION II: 16:00-17.30 EPIDEMIOLOGY Chair: Delmee, M.			
16.00-16-30	INV3	Riley, T.	THE "ONE HEALTH" PARADIGM AND <i>C. difficile</i>
16.30-16.50	OP1	Martín-Burriel, I.	COMPARATIVE GENOME ANALYSIS OF <i>Clostridium difficile</i> STRAINS ISOLATED FROM DOMESTIC AND WILD ANIMALS REVEALS HIGH SIMILARITY WITH HUMAN STRAINS
16.50-17.10	OP2	Banks, A.	COMMUNITY ASSOCIATED <i>Clostridium difficile</i> INFECTION (CDI) IN SCOTLAND – A SENTINEL STUDY
17.10-17-30	OP3	Cairns, M.	THE GLOBAL PHYLOGENY OF <i>Clostridium difficile</i> TOXIN A-B+ PCR RIBOTYPE 017
17:30-18:00 BREAK / refreshments served in poster area			
SESSION III : 18.00-19.10 SPORULATION/GERMINATION Chair: Kuehne, S.			
18.00-18.30	INV4	McBride, S.	NOVEL REGULATORY MECHANISMS CONTROL SPORULATION INITIATION IN <i>C. difficile</i>
18.30-18.50	OP4	Salgado, P.	THE MOTHER CELL TO FORESPORE CHANNEL HAS A CENTRAL ROLE IN SPORE MORPHOGENESIS, PROTEIN LOCALISATION AND PEPTIDOGLYCAN REMODELING
18.50-19.10	OP5	Sorg, J.	SPORE CORTEX HYDROLYSIS PRECEDES DPA RELEASE DURING <i>C. difficile</i> SPORE GERMINATION
19:30 WELCOME RECEPTION (Hotel Golf)			

Wednesday, 20th May

SESSION IV: 9:00-10:40 IMMUNOLOGY Chair: Kato, H.			
9.00-9.20	OP6	Pedneault, L.	A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A <i>Clostridium difficile</i> VACCINE ADMINISTERED WITH OR WITHOUT ALUMINUM HYDROXIDE, IN A 3-DOSE REGIMEN IN HEALTHY ADULTS AGED 50 TO 85 YEARS
9.20-9.40	OP7	Therien, A.	EPITOPES AND MECHANISMS OF ACTION OF THE <i>Clostridium difficile</i> TOXIN-NEUTRALIZING ANTIBODIES ACTOXUMAB AND BEZLOTOXUMAB
9.40-10.00	OP8	Quemeneur, L.	<i>Clostridium difficile</i> TOXOID VACCINE CONFERS CROSS- PROTECTION AGAINST PREVALENT CIRCULATING <i>C. difficile</i> VARIANT STRAINS IN NON-CLINICAL SETTINGS
10.00-10.20	OP9	von Eichel-Streiber, A.	DIFFERENTIAL SYSTEMIC AND MUCOSAL ANTI-TOXIN RESPONSES AMONG PATIENTS INFECTED WITH THE EPIDEMIC 027 STRAIN OF <i>C. difficile</i>
10.20-10.40	OP10	Bajaj-Elliott, M.	<i>Clostridium difficile</i> -INDUCED ER STRESS PROMOTES MACROPHAGE NLRP3 MEDIATED INFLAMMASOME ACTIVATION
10:40-11:15 COFFEE BREAK			
SESSION V: 11:15-12:15 CLINICAL ASPECTS/TREATMENT AND DIAGNOSTICS Chair: Dubberke, E.			
11.15-11.45	INV5	Guery, B.	TREATMENT OF CDI - PRESENT AND FUTURE
11.45-12.15	INV6	Louie, T.	PRACTICAL ASPECTS OF FECAL MICROFLORA TRANSPLANTATION (FMT) FOR CDI
12:15-14:00 LUNCH (Hotel Golf)			
SESSION VI: 14:00-15:40 CLINICAL ASPECTS/PREVENTION Chair: Johnson, S.			
14.00-14.30	INV7	Fitzpatrick, F.	THE CARROT OR STICK? USING HEALTHCARE-ASSOCIATED <i>C. difficile</i> INFECTION RATES AS A PERFORMANCE MANAGEMENT TOOL
14.30-15.00	INV8	Dubberke, E.	TRANSMISSION AND FUTURE PREVENTION STRATEGIES
15.00-15.20	OP11	Khanafer, N.	FACTORS ASSOCIATED WITH SEVERE <i>Clostridium difficile</i> INFECTION ACCORDING TO 4 DIFFERENT SEVERITY DEFINITIONS
15.20-15.40	OP12	Ivarsson, M.	THERAPEUTIC POTENTIAL OF SMALL MOLECULE TRIGGERS OF PRE-EMPTIVE <i>C. difficile</i> TOXIN B AUTO-PROTEOLYSIS
15:40-17:00 POSTER SESSION I (coffee served in poster area)			
ROUND TABLE: 17:00-18:30 DIAGNOSTICS			
17.00-17.20	INV9	Barbut, F.	DIAGNOSIS OF <i>Clostridium difficile</i> INFECTIONS: WHEN AND HOW?
17.20-18.30		Barbut, F. (moderator)	ROUND TABLE DISCUSSION
19:00 DINNER (Hotel Golf)			

Thursday, 21st May**SESSION VII: 9:00-10:30 PATHOGENESIS AND VIRULENCE FACTORS Chair: Collignon, A.**

9.00-9.30	INV10	Janoir, C.	<i>C. difficile</i> VIRULENCE FACTORS
9.30-9.50	OP13	Corver, J.	A NOVEL SECRETED METALLOPROTEASE (CD2830) FROM <i>Clostridium difficile</i> CLEAVES SPECIFIC PROLINE SEQUENCES IN LPXTG CELL SURFACE PROTEINS
9.50-10.10	OP14	Kirk, J.A.	THE <i>Clostridium difficile</i> S-LAYER: A MULTI-FUNCTIONAL VIRULENCE FACTOR AND ANTI-BACTERIAL TARGET
10.10-10.30	OP15	Sekulovic, O.	THE PHASE-VARIABLE CELL WALL PROTEIN CwpV CONFERS PHAGE RESISTANCE TO <i>Clostridium difficile</i>

10:30-11:00 COFFEE BREAK**SESSION VIII: 11:00-12:30 INDUSTRY MEETS SCIENCE Chair: Wilcox, M. H.****12:30-14:00 LUNCH****SESSION IX 14:00-15:10 PHYSIOLOGY Chair: Mastrantonio, P.**

14.00-14.30	INV11	Spigaglia, P.	ANTIBIOTIC RESISTANCE IN <i>C. difficile</i> – RECENT ADVANCES
14.30-14.50	OP16	Faulds-Pain, A.	INVESTIGATING THE POST-TRANSLATIONAL MODIFICATION OF THE <i>Clostridium difficile</i> FLAGELLIN
14.50-15.10	OP17	Peltier, J.	CYCLIC-DI-GMP REGULATES PRODUCTION OF SORTASE B SUBSTRATES OF <i>Clostridium difficile</i> AND THEIR SURFACE EXPOSURE THROUGH ZMPI PROTEASE-MEDIATED CLEAVAGE

15:10-16:30 POSTER SESSION II (coffee served in poster area)**SESSION X: 16:30-18:00 MICROBIOTA Chair: Rupnik, M.**

16.30-17.00	INV12	Young V.	<i>C. difficile</i> INFECTION: THE TANGLED WEB OF EPITHELIUM, MICROBIOTA AND PATHOGEN
17.00-17.20	OP18	Carlucci, C.	CHARACTERIZATION OF A DEFINED MICROBIAL ECOSYSTEM THERAPEUTIC FOR THE TREATMENT OF <i>Clostridium difficile</i> INFECTION
17.20-17.40	OP19	Govoni, G.	AVIDOCIN-CDs: TARGETABLE, MICROBIOTA-FRIENDLY BACTERICIDAL AGENTS FOR TREATMENT AND PREVENTION OF CDI
17.40-18.00	OP20	Chilton, C.	POSSIBLE FAECAL MICROBIOTA MEDIATED INHIBITION OF THE BIOACTIVITY OF <i>Clostridium difficile</i> INFECTION (CDI) ANTIBIOTIC TREATMENT AGENTS

19.30 CONGRESS DINNER (Grand Hotel Toplice)**Friday, 22nd May****Trip to Franja Partisan Hospital (attendance confirmation by May 19th at the registration desk)**